Pharmaceuticals, Biotechnology and Life Sciences
Moderna, Inc., (Nasdaq:MRNA) has announced that Jorge Gomez will join Moderna as Chief Financial Officer, effective Monday, May 9, 2022. He will serve on Moderna’s Executive Committee and report to Chief Executive Officer, Stéphane Bancel.
Pfizer Inc. (NYSE: PFE) announced updated results from the Phase 3 CROWN trial, which evaluated LORBRENA (lorlatinib, available in Europe under the brand name LORVIQUA) versus XALKORI (crizotinib) in people with previously untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”) have announced the results of the prespecified final progression-free survival (“PFS”) analysis and the interim overall survival (“OS”) analysis of the JUPITER-02 study (NCT03581786), a pivotal Phase 3 trial in first-line treatment of recurrent or metastatic nasopharyngeal carcinoma (“NPC”).
Elastrin Therapeutics Inc., a privately held biotechnology company leveraging a platform to develop therapeutics that render calcified tissue and organs supple again, has announced the closing of a $10 million funding round led by Kizoo Technology Capital, a early-stage investor in breakthrough rejuvenation technologies. Other investors in the round include Starbloom Capital and SC Launch.
Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and the nonprofit scientific research organization IAVI have announced a new collaboration to employ mRNA technology to meet the challenge of a range of global health threats.
Pfizer Inc. has entered into a definitive agreement to acquire Andera Life Sciences’ portfolio company ReViral Ltd.
Elastrin Therapeutics Inc., a privately held biotechnology company leveraging a platform to develop therapeutics that render calcified tissue and organs supple again, has announced the closing of a $10 million funding round led by Kizoo Technology Capital, a early-stage investor in breakthrough rejuvenation technologies.
FDA said that GSK’s sotrovimab is not authorized in any U.S. state or territory at this time, as CDC’s data showed the authorized dose of sotrovimab is unlikely to be effective against the BA.2 sub-variant.
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Novartis-s Vijoice (alpelisib) for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy.
The European Commission (EC) has approved Bristol Myers Squibb’s Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) with tumor cell PD-L1 expression ≥ 1%.